Skip to Content

Phase I Safety Pharmacokinetic and Pharmacodynamic study of PF-02341066 a C-Met/HGFR selective Tyrosine Kinase inhibitor administered orally to patients with advanced cancer.

Objective
Clinical trial of investigational drug PF-02341066 given by mouth.
IRB Protocol Number
06-0155
Principal Investigator(s)
ROSS CAMIDGE

Cancer Trials

  • All Cancers
Sponsor(s)
Pfizer
Contact
SARAH RIPPKE at 720-848-0685
or RIPPKE.SARAH@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility, which may include a tumor biopsy. A treatment period that can last up to 1 year as long as you are responding well to the study drug. A follow up period will consist of a clinic visit 28 days after you stop treatment. // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).

Location

  • Clinical Translational Research Center (CTRC)